2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Melanoma
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Carcinoma, Renal Cell
6
Kidney Neoplasms
4
Leukemia, Myeloid, Chronic-Phase
3
Carcinoma, Hepatocellular
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Polycythemia Vera
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Leukemia
2
Hepatitis B, Chronic
2
Fallopian Tube Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplasms
1
Interventions
fludarabine phosphate
25
Cyclophosphamide
24
Peripheral Blood Stem Cell Transplantation
23
Busulfan
17
Tacrolimus
15
Methotrexate
13
Cyclosporine
13
ruxolitinib
12
Whole-Body Irradiation
12
Mycophenolic Acid
12
Antilymphocyte Serum
11
Filgrastim
8
Decitabine
7
fludarabine
6
Etoposide
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
peginterferon alfa-2a
5
Radiotherapy
5
Methylprednisolone
5
Cytarabine
5
Carboplatin
5
Prednisone
4
Melphalan
4
Flow Cytometry
4
Biopsy
4
Aspirin
4
givinostat hydrochloride
3
givinostat
3
bomedemstat
3
anagrelide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thrombocythemia, Essential
×
peginterferon alfa-2b
×
Clear all
NCT01387763
2022-04-27
DALIAH
Odense University Hospital
Phase 3
Completed
202 enrolled